More than 2.8 million courses of Pfizer Inc’s (PFE.N) COVID-19 oral antiviral treatment Paxlovid have been made available at pharmacies around the United States, with the Biden administration working to improve access to the drug.
As Paxlovid has become more widely used, some patients have reported that COVID-19 symptoms recurred after completing treatment and experiencing improvement. Here is the latest information on these rebounds…
